Diabetic Med:1型糖尿病青少年的治疗

2018-10-24 MedSci MedSci原创

为了更好地了解糖尿病患者自我护理的驱动因素和障碍,近日,国际杂志 《Diabetic Med》上在线发表一项关于1型糖尿病青少年的治疗偏好-使用离散选择实验模型的国家研究。使用离散选择实验模型对全国范围内1型糖尿病的青少年中进行测试。 在一小部分目标人群中(年龄在15至<18岁且患有1型糖尿病的青少年)构建并测试了调查工具。然后通过瑞典儿科糖尿病质量登记处SWEDIABKIDS识别瑞典

为了更好地了解糖尿病患者自我护理的驱动因素和障碍,近日,国际杂志 《Diabetic Med》上在线发表一项关于1糖尿病青少年的治疗偏好-使用离散选择实验模型的国家研究。使用离散选择实验模型对全国范围内1糖尿病的青少年中进行测试。

在一小部分目标人群中(年龄在15<18岁且患有1型糖尿病的青少年)构建并测试了调查工具。然后通过瑞典儿科糖尿病质量登记处SWEDIABKIDS识别瑞典属于该目标组(N=2112)的所有个体,并且发送邀请以回答在线问卷。研究共获得了对431个人进行了离散选择实验分析的有效响应。

研究结果表明,纳入的受访者在年龄和糖尿病病程方面与非参与者没有统计学差异,但年轻女性进入研究较多,参与者(平均)HbA 1c值明显低于非参与者。参与者认为非严重低血糖事件(白天和夜晚)和高血糖事件都是不可取的。女性受访者中,避免体重增加,甚至实现体重减轻是最重要的方面,她们愿意以大幅度的血糖控制[13 mmol / mol1.2%)]进行换取,以避免体重增加3 kg

鉴于现实生活中的两难困境,这些回答可能会为受访者优先考虑的方面提供有用的提示。对于治疗效果,按性别划分的分层很重要,而治疗管理方面应根据治疗类型进行分层,因为这些方面是密切相关的。

原始出处:

G. Forsander S. Stallknecht U. Samuelssonet al. Preferences for treatment among adolescents with Type 1 diabetes: a national study using a discrete choice experiment model

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1970619, encodeId=2c9519e0619c4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 30 03:58:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760829, encodeId=a0711e6082933, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 20 05:58:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638786, encodeId=1a2e1638e866d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 30 15:58:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609222, encodeId=b608160922215, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 26 04:58:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041946, encodeId=0e2510419468a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 24 16:58:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1970619, encodeId=2c9519e0619c4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 30 03:58:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760829, encodeId=a0711e6082933, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 20 05:58:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638786, encodeId=1a2e1638e866d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 30 15:58:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609222, encodeId=b608160922215, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 26 04:58:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041946, encodeId=0e2510419468a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 24 16:58:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1970619, encodeId=2c9519e0619c4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 30 03:58:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760829, encodeId=a0711e6082933, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 20 05:58:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638786, encodeId=1a2e1638e866d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 30 15:58:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609222, encodeId=b608160922215, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 26 04:58:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041946, encodeId=0e2510419468a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 24 16:58:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1970619, encodeId=2c9519e0619c4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 30 03:58:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760829, encodeId=a0711e6082933, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 20 05:58:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638786, encodeId=1a2e1638e866d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 30 15:58:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609222, encodeId=b608160922215, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 26 04:58:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041946, encodeId=0e2510419468a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 24 16:58:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1970619, encodeId=2c9519e0619c4, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Jan 30 03:58:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760829, encodeId=a0711e6082933, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 20 05:58:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638786, encodeId=1a2e1638e866d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Aug 30 15:58:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609222, encodeId=b608160922215, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 26 04:58:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041946, encodeId=0e2510419468a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 24 16:58:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2018-10-24 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

这种病误诊率达20% 连英国首相也中枪

糖尿病这种病,简直不能更常见了。即便如此,对于专业医生来说,判断成年患者属于1型糖尿病还是2型糖尿病也并非易事。最新研究显示,成年患者糖尿病类型误诊的现象很普遍。2012年,英国首相特雷莎·梅(Theresa May)被诊断为2型糖尿病。那时她50多岁,虽然所有病症也符合1型糖尿病,包括体重快速降低等,初诊时梅为2型糖尿病。但梅吃过处方药后症状并未缓解,医生于是安排了更多检查,最后却发现她患的是1

Diabetic Med:1型糖尿病成人胰岛素抗体水平与胰岛素敏感性反向关联?

近日,国际杂志 《Diabetic Med》上在线发表一项关于1型糖尿病成人胰岛素抗体水平与胰岛素敏感性的反向关联的研究。 胰岛素抵抗可能有助于解释自身免疫介导的糖尿病的发病机制。对β细胞相关分子的抗体,包括胰岛细胞抗原(ICA),谷氨酸脱羧酶(GAD)和胰岛素,能够表明自身免疫过程的特点。由于胰岛素抵抗和自身免疫之间的联系可能与疾病进展和治疗有关,研究人员假设胰岛素抵抗与新诊断的1型糖尿病

Diabetic Med:对低血糖意识受损的1型糖尿病患者动态血糖监测和快速血糖监测的RCT研究结果

1型糖尿病患者血糖过低会导致发病和死亡,尤其是在低血糖意识障碍的情况下。目前,获得动态血糖监测(CGM)和快速葡萄糖监测技术的临床途径尚不清楚。近日,国际杂志 《Diabetic Med》上在线发表一项关于对低血糖意识受损的1型糖尿病患者动态血糖监测和快速血糖监测的RCT研究结果。研究人员评估了CGM和快速葡萄糖监测对1型糖尿病高风险人群的影响。 研究人员通过一项随机,非掩蔽的平行组研究。

Diabetes Care:1型糖尿病和精神病合并症儿童和青少年代谢控制不良

由此可见,1型糖尿病发病后2年内平均HbA1c水平较高可能表明后期会患精神病合并症。1型糖尿病的儿童和青少年的精神病合并症会增加不良代谢结局的风险。早期关注疾病负担可能会改善结局。

Neurology:创伤性脑损伤与1型糖尿病患者痴呆风险相关

由此可见,该研究表明中老年T1D患者罹患TBI后痴呆风险显著增加。鉴于患有T1D的个体的自我护理的复杂性以及使他们易于发生创伤和跌倒的合并症,未来的工作需要研究保护这个弱势群体的大脑健康的干预措施。

Diabetes Care:年轻1型糖尿病患者终末期肾病累积发病率降低

由此可见,在瑞典1型糖尿病患者人群中发生ESRD的风险仍然很低,而且似乎也随着时间的推移而有所降低。